Novavax (NVAX) Misses Q4 EPS by 99c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $8.90 -1.11%
Revenue Growth %: -78.2%
Financial Fact:
Interest expense: -3.51M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: -78.2%
Financial Fact:
Interest expense: -3.51M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q4 EPS of ($1.44), $0.99 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $291 million versus the consensus estimate of $321.97 million.
GUIDANCE:
Novavax sees FY2024 revenue of $0.8-1 billion, versus the consensus of $0.97 billion.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras CEO says investors misunderstood margin guidance
- Currenc Group suspends Indonesian WalletKu unit operations
- H.B. Fuller (FUL) Tops Q2 EPS by 3c; Offers Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
